Biomedical Sciences Doctoral Program, Faculty of Medicine, Andalas University, Padang, Indonesia.
Orthopaedic and Traumatology Division, Department of Surgery, M. Djamil General Hospital, Faculty of Medicine, Andalas University, Padang, Indonesia.
J Orthop Surg Res. 2024 Nov 1;19(1):710. doi: 10.1186/s13018-024-05149-1.
This study aims to assess the effectiveness of therapy of human synovial membrane-derived MSCs (SM-MSC) from OA grade IV patients in treating knee OA.
SM-MSC were isolated from patients undergoing total knee replacement surgery, cultured to the fourth passage, and characterized using flow cytometry. Differentiation potential was assessed through lineage-specific staining. Osteoarthritis was induced in 24 Wistar rats via monosodium iodoacetate (MIA). The rats were divided into three groups: negative control, OA control, and OA treated with SM-MSC. Radiological, histopathological, and molecular analyses were conducted to evaluate cartilage repair and gene expression.
Flow cytometry confirmed the MSC phenotype of SM-MSC, and successful differentiation was observed. Radiological and histopathological analyses showed significant improvement in the SM-MSC treated group, with reduced cartilage damage and higher Safranin O staining compared to the OA control group. Gene expression analysis indicated increased type-2 collagen (COL-2) expression in the SM-MSC treated group, although MMP-13 levels remained unchanged across all groups.
Human SM-MSCs from OA grade IV patients significantly improved cartilage repair in an OA rat model, demonstrating their potential as a therapeutic option for OA. To enhance long-term efficacy and anti-inflammatory effects, further studies are needed to optimize treatment protocols, including injection frequency and dosage.
本研究旨在评估来自 OA Ⅳ级患者的滑膜间充质干细胞(SM-MSC)治疗膝骨关节炎的疗效。
从接受全膝关节置换术的患者中分离 SM-MSC,培养至第 4 代,通过流式细胞术进行鉴定。通过谱系特异性染色评估其分化潜能。通过碘乙酸单钠(MIA)诱导 24 只 Wistar 大鼠发生骨关节炎。将大鼠分为三组:阴性对照组、OA 对照组和 OA 用 SM-MSC 治疗组。进行放射学、组织病理学和分子分析以评估软骨修复和基因表达。
流式细胞术证实了 SM-MSC 的 MSC 表型,并观察到其成功分化。放射学和组织病理学分析显示,SM-MSC 治疗组有明显改善,与 OA 对照组相比,软骨损伤减少,番红 O 染色增加。基因表达分析表明,SM-MSC 治疗组的 II 型胶原(COL-2)表达增加,但 MMP-13 水平在所有组中均保持不变。
来自 OA Ⅳ级患者的人 SM-MSCs 显著改善了 OA 大鼠模型中的软骨修复,表明其作为 OA 治疗选择的潜力。为了提高长期疗效和抗炎效果,需要进一步研究以优化治疗方案,包括注射频率和剂量。